Mnemosyne Pharmaceuticals (Providence, RI) a development-stage small molecule company focused on neuropsychiatric disorders such as schizophrenia and Alzheimer’s, closed a $5.4M Series financing Participants include Access BridgeGap Ventures and Slater Technology Fund. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.
Concert Pharmaceuticals (Lexington, MA) development-stage pharmaceutical company focused on new chemical entities based upon modifications of validated drug molecules using deuterium chemistry, closed a $37M Series C financing. Participants include Adage Capital Management, SR One, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, Flagship Ventures, Greylock […]